We partnered with our client, an emerging and specialised diagnostics company, to understand & analyse competitor data releases and presentations at top oncology conferences.
The Opportunity:
“What data are new & existing entrants to the next-generation sequencing space generating in cancer screening & monitoring and how are they clinically and commercially positioning their products?”
The client wanted Eradigm to deliver a comprehensive and live analysis of two major international oncology conferences, with analysis of data presented by competitors and their messaging to HCPs. Eradigm covered major sessions and conducted primary research with HCPs and competitor sources to understand the end-user perspective as well as further test development plans
Our Approach:
Eradigm partnered with the Commercial Strategy & CI teams before, during and after the conference, engaging key stakeholders from cross-functional teams to deliver insights and analysis.
Eradigm facilitated the conference organization, including tech-enabled creation of a conference planner of key sessions with assigned prioritizations based on open discussions of the clients goals and priorities. During the conference, an in-person attendee attended competitor sessions to prepare summaries with the key data, takeaways and implications for the client, which were crafted into high-impact daily summaries for the wider stakeholder team. Eradigm consultants conducted in-person primary research with competitor sources to obtain valuable insights on development plans and timelines, which were triangulated and communicated to the client in real time.
We delivered a comprehensive post-conference report, which was presented to the wider stakeholder team, including senior representatives from R&D, commercial, and medical teams. The report synthesized insights from primary research as well as analysis of competitor presentations and posters to provide detailed status updates on each competitor in the next-generation sequencing space within oncology.
The Impact:
This project helped a specialised, leading diagnostics player to better understand their poisoning within the oncology diagnostics space in comparison to newer and less commercially advanced competitors. The insights supported tactical decision-making by both medical and commercial teams, including adjusting strategies for data generation, as well as commercial activities based on upcoming competitor events such as regulatory submissions. The client highly valued our work, leading to project extension and coverage of several subsequent conferences. This project further solidified Eradigm’s expert knowledge in oncology, but also next-generation diagnostics, combining exacting scientific analysis with strategic decision making support.
